Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04606914 |
|
Recruitment Status :
Recruiting
First Posted : October 28, 2020
Last Update Posted : November 30, 2023
|
Sponsor:
University of Alabama at Birmingham
Information provided by (Responsible Party):
Rebecca Arend, University of Alabama at Birmingham
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | May 31, 2026 |
| Estimated Study Completion Date : | May 31, 2028 |